Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease

NCT00392509 is registered in ClinicalTrials.gov with Aldagen as lead sponsor.

NCT NCT00392509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00392509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease
Lead sponsor
Aldagen
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2006
Completion date
December 31, 2008
Enrollment
20 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia, peripheral arterial disease, peripheral vascular disease